Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-D-aspartate receptor antagonists: preferential involvement of the NR2B rather than NR2A subunit

Autor: F, Chaperon, W, Müller, Y P, Auberson, M D, Tricklebank, H C, Neijt

Publikováno v: Behavioural pharmacology. 14(5-6)

The non-competitive NMDA receptor antagonist phencyclidine (PCP) is known to produce a discriminative stimulus in rats. The first aim of the present study was to investigate which NMDA receptor subtype(s) is involved in this effect of PCP. Rats were

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::dbff392a1e33705e393f08b7147386ba
https://pubmed.ncbi.nlm.nih.gov/14501261

Disruption of prepulse inhibition and increases in locomotor activity by competitive N-methyl-D-aspartate receptor antagonists in rats

Autor: V P, Bakshi, M, Tricklebank, H C, Neijt, V, Lehmann-Masten, M A, Geyer

Publikováno v: The Journal of pharmacology and experimental therapeutics. 288(2)

Noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine are psychotomimetics and disrupt prepulse inhibition (PPI), a measure of sensorimotor gating that is deficient in schizophrenia. Systemically administered competiti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7d6ad2546754a130bf12eecbb88e73b2
https://pubmed.ncbi.nlm.nih.gov/9918570

Abstracts of papers pharmacological meeting

Autor: G. J. Blauw, P. van Brummelen, P. Vermeij, P. A. van Zvieten, H. W. C. M. Boddeke, H. N. Doods, P. A. van Zwieten, A. H. Bom, D. J. Duncker, P. D. Verdouw, P. R. Saxena, M. J. A. P. Daemen, H. T. M. Vervoort-Peters, H. H. W. Thijssen, D. Davidesko, H. D. Batink, H. D. Bangik, K. J. van Charldrop, S. F. de Boer, J. L. Slangen, J. van der Gugten, W. S. De Loos, B. Bohus, W. De Jong, D. De Wied, M. A. H. de Zwart, H. van der Goot, H. Timmerman, A. Garritsen, A. P. IJzerman, W. Soudijn, J. B. Heynis, H. W. G. M. Boddeke, B. J. A. Janssen, H. van Essen, H. A. J. Struyker Boudier, J. F. M. Smits, T. J. W. Jap, C. E. J. Ketelaars, J. Bruinvels, M. J. Krielaart, D. M. J. Veenstra, G. J. T. H. Stolze, L. M. L. le Noble, D. W. Slaaf, G. J. Tangelder, H. C. Neijt, I. J. te Duits, J. J. Plomp, H. P. M. Vijverberg, J. A. M. Raaijmakers, R. J. E. van den Eijnde, F. S. Radhakishun, J. C. Stoof, A. H. Mulder, D. H. G. Versteeg, J. M. van Ree, F. A. M. Redegeld, J. Noordhoek, J. M. H. M. Reul, J. A. D. M. Tonnaer, E. R. de Kloet, J. Riezebos, A. de Jonge, C. G. J. Sweep, V. M. Wiegant, F. Th. M. van Amsterdam, M. Haas, J. Zaagsma, R. G. M. van Amsterdam, F. Brouwer, K. J. van Charldorp, R. van de Straat, J. de Vries, N. P. E. Vermeulden, P. L. M. van Giersbergen, J van Harten, RRECM Zeegers, P van Brumnelen, DD Breimer, P. N. M. van Heiningen, E. J. van Hoogdalem, A. G. de Boer, D. D. Breimer, J. van Wijngaarden, H. Wesseling

Publikováno v: Pharmaceutisch Weekblad. 8:270-278

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4fba487c10f884e8c4f524c81f871237
https://doi.org/10.1007/bf01960072